Boston Scientific Announces Scheduled Data at EHRA 2019 Congress

- Two late-breaking clinical trials will be presented, including: "We are especially looking forward to the first ever presentation of data showcasing the performance of one of our new single-shot ablation technologies, the LUMINIZE RF Balloon Catheter, for the treatment of AF," said Dr. Kenneth Stein, senior vice president and chief medical officer, Rhythm Management and Global Health Policy, Boston Scientific. "Those data, as well as the data showing the relationship between AF and worsening heart failure detected by our multisensor HeartLogic Heart Failure Diagnostic, demonstrate our commitment to providing personalized treatment and the highest possible care for patients with cardiac rhythm disorders and heart failure." PRESENTATIONS OF INTEREST  All late-breaking presentations will take place in the Sokolov Lecture Room: Sunday, 17 March Tuesday, 19 March All presentations are listed in Central European Time (CET) and will take place at Centro de Congressos de Lisboa, Praça de Indústrias, 1300-307 Lisbon, Portugal. The LUMINZE RF Balloon Catheter is pending CE Mark and is not available for use or sale.  For more information, visit Boston Scientific at booth #B100 or follow @BSC_EU_Heart. About Boston Scientific Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for 40 years, we advance science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.  For more information, visit www.bostonscientific.com and connect on Twitter and Facebook. CONTACTS: European Media: Rosie IrelandBoston Scientific Europe+44 (0)7585 [email protected]  U.S. Media:Laura AumannBoston Scientific (651) 328-0619 (office)[email protected]  Susie Lisa, CFAInvestor RelationsBoston Scientific Corporation(508) 683-5565 (office)[email protected]